Gene Transfer Trials Should Require Sequencing Of Small Vectors - Cmte.
Executive Summary
FDA should require complete sequencing of gene transfer vectors up to 40 kilo bases in size before initiation of a Phase I gene transfer therapy clinical trial, the Biological Response Modifiers Advisory Committee recommended Nov. 16.
You may also be interested in...
Adenoviral Gene Therapy Death Will Be Explored By NIH rDNA Committee
Safety and efficacy of adenoviral vectors for therapeutic application will be examined at the Dec. 9-10 meeting of the NIH Recombinant DNA Advisory Committee. The action follows the death of a teenager enrolled in a gene therapy trial at the University of Pennsylvania Medical Center.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials